Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 3/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 3/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445161 | 0.78 | MIF (0.56) | MIFIDO1CYP1A2CYP2C19ALOX15 | |
| SCHEMBL6674627 | 0.78 | SMN1; SMN2 (0.60) | MIFIDO1SMN1; SMN2MAPTNR1I2 | |
| SCHEMBL27871811 | 0.78 | HPGD (0.45) | KDM1AIDO1SMN1; SMN2MAPTNR1I2 | |
| SCHEMBL1445151 | 0.78 | MIF (0.56) | MIFIDO1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL28132401 | 0.74 | HTR2B (0.47) | KDM1AIDO1SMN1; SMN2MAPTNR1I2 | |
| SCHEMBL20705126 | 0.74 | SMARCA2 (0.47) | KDM1AIDO1SMN1; SMN2MAPTSMARCA2 | |
| SCHEMBL244108 | 0.72 | MIF (1.00) | MIFSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL1445127 | 0.71 | MIF (0.49) | MIFMAPTCYP1A2CYP2C19HSD17B10 | |
| SCHEMBL22182447 | 0.70 | MIF (0.47) | MIF | |
| SCHEMBL20813388 | 0.69 | MIF (0.60) | MIFSMN1; SMN2MAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | claimed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | claimed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9155790-B2 | Methods and compositions for modulating ocular damage | University of Lousiville Research Foundation, Inc. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011146824-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | MIF, MSR1, CCL2 | MIF 1/4885KDM1A 3512/4885IDO1 58/4885 |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | MIF, MMP1, CXCL12 | MIF 1/4885KDM1A 3660/4885IDO1 206/4885 |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | MIF 1/4885KDM1A 3199/4885IDO1 63/4885 |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | MIF 1/4885KDM1A 3199/4885IDO1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.